What the FDA labels say about taking them together
Tenecteplase and warfarin
Tenecteplase's FDA label of December 15, 2025 names warfarin in its warnings and precautions section; the warfarin label PlainMeds reads does not name tenecteplase. The tenecteplase label: “… infected site Advanced age Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because …”
Check it at the source: the tenecteplase FDA label on DailyMed (effective December 15, 2025, Genentech, Inc.); the warfarin FDA label on DailyMed (effective May 29, 2026, Amneal Pharmaceuticals LLC).
What does the tenecteplase label say about warfarin?
Tenecteplase label, warnings and precautions… retinopathy, or other hemorrhagic ophthalmic conditions Septic thrombophlebitis or occluded AV cannula at seriously infected site Advanced age [see Use in Specific Populations (8.5) ] Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location.
Source: FDA drug label (TNKase), Genentech, Inc., effective December 15, 2025 (SPL set e647640d-c395-4b4b-a0be-1162f9c21d84), via openFDA; the full label on DailyMed
What does the warfarin label say about tenecteplase?
Warfarin's label (effective May 29, 2026) does not name tenecteplase in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Warfarin Sodium), Amneal Pharmaceuticals LLC, effective May 29, 2026 (SPL set 558b7a0d-5490-4c1b-802e-3ab3f1efe760), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Tenecteplase | Warfarin | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.093 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once